Population pharmacokinetics of ganciclovir following administration of valganciclovir in paediatric renal transplant patients

Clinical Pharmacokinetics

Volumn 48, Issue 5, 2009, Pages 321-328

  Zhao, Wei ^a   Baudouin, Véronique ^a   Zhang, Daolun ^a   Deschênes, Georges ^a   Le Guellec, Chantal ^b   Jacqz Aigrain, Evelyne ^a  

^a Hpital Robert Debr ^*  (France)

^b UNIVERSITÉ DE TOURS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN A; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ADOLESCENT; ARTICLE; BODY WEIGHT; BOOTSTRAPPING; CHILD; CLINICAL ARTICLE; COMPUTER PROGRAM; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; FEMALE; GRAFT RECIPIENT; HUMAN; INFECTION PREVENTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; PLASMA CONCENTRATION-TIME CURVE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SIMULATION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; GANCICLOVIR; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; MALE; POPULATION GROUPS; TISSUE DISTRIBUTION;

EID: 67650251911     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/00003088-200948050-00004     Document Type: Article

References (28)

1. Fishman JA, Rubin RH. Infection in organ transplant recipients. N Engl J Med 1998; 338: 1741-51
2. Preiksaitis JK, Brennan DC, Fishman J, et al. Canadian Society of Transplantation consensus workshop on cytomegalovirus management in solid organ transplantation, final report. Am J Transplant 2005; 5: 218-27
3. Burd RS, Gillingham KJ, Farber MS, et al. Diagnosis and treatment of cytomegalovirus disease in pediatric renal transplant recipients. J Pediatr Surg 1994; 29: 1049-54
4. Noble S, Faulds D. Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 1998; 56: 115-46
5. Kletzmayr J, Kreuzwieser E, Watkins-Riedel T, et al. Long-term oral ganci-clovir prophylaxis for prevention ofcytomegalovirus infection and disease in cytomegalovirus high-risk renal transplant recipients. Transplantation 2000; 27: 1174-80
6. Brennan DC, Garlock KA, Lippmann BA, et al. Control of cytomegalovirus-associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy. J Am Soc Nephrol 1997; 8: 118-25
7. Dunn DL, Mayoral JL, Gillingham KJ, et al. Treatment of invasive cytomegalovirus disease in solid organ transplant patients with ganciclovir. Transplantation 1991; 51: 98-106
8. Hecht DW, Snydman DR, Crumpacker CS, et al. Ganciclovir for treatment of renal transplant-associated primary cytomegalovirus pneumonia. J Infect Dis 1988; 157: 187-90
9. Drew WL, Stempien MJ, Andrews J, et al. Cytomegalovirus (CMV) resistance in patients with CMV retinitis and AIDS treated with oral or intravenous ganciclovir. J Infect Dis 1999; 179: 1352-5
10. Pescovitz MD, Pruett TL, Gonwa T, et al. Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function. Transplantation 1998; 66: 1104-7
11. Limaye AP, Corey L, Koelle DM, et al. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000; 356: 645-9
12. Fishman JA, Doran MT, Volpicelli SA, et al. Dosing of intravenous ganciclovir for the prophylaxis and treatment of cytomegalovirus infection in solid organ transplant recipients. Transplantation 2000; 69: 389-94
13. Wiltshire H, Paya CV, Pescovitz MD, et al. Pharmacodynamics of oral ganci-clovir and valganciclovir in solid organ transplant recipients. Transplantation 2005; 79: 1477-83
14. Wiltshire H, Hirankarn S, Farrell C, et al. Pharmacokinetic profile of ganciclo-vir after its oral administration and from its prodrug valganciclovir, in solid organ transplant recipients. Clin Pharmacokinet 2005; 44: 495-507
15. Vethamuthu J, Feber J, Chretien A, et al. Unexpectedly high inter- and intra-patient variability of ganciclovir levels in children. Pediatr Transplant 2007; 11: 301-5
16. Sommadossi JP, Bevan R, Ling T, et al. Clinical pharmacokinetics ofganciclo-vir in patients with normal and impaired renal function. Rev Infect Dis 1988; 10: S507-14
17. Winston DJ, Ho WG, Bartoni K, et al. Ganciclovir therapy for cytome-galovirus infections in recipients of bone marrow transplants and other immunosuppressed patients. Rev Infect Dis 1988; 10: S547-53
18. Zhang D, Lapeyraque AL, Popon M, et al. Pharmacokinetics ofganciclovir in pediatric renal transplant recipients. Pediatr Nephrol 2003; 18: 943-8
19. Yano Y, Beal SL, Sheiner LB. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 2001; 28: 171-92
20. Charles BG, Miller AK, Nasveld PE, et al. Population pharmacokinetics of tafenoquine during malaria prophylaxis in healthy subjects. Antimicrob Agents Chemother 2007; 51: 2709-15
21. Hennig S, Wainwright CE, Bell SC, et al. Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients. Clin Pharmacokinet 2006; 45: 1099-114
22. Ette EI. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol 1997; 37: 486-95
23. Czock D, Scholle C, Rasche FM, et al. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment. Clin Pharmacol Ther 2002; 72: 142-50
24. Wolfe EJ, Mathur V, Tomlanovich S, et al. Pharmacokinetics of mycophe- nolate mofetil and intravenous ganciclovir alone and in combination in renal transplant recipients. Pharmacotherapy 1997; 17: 591-8
25. Crumpacker CS. Ganciclovir. N Engl J. Med 1996; 335: 721-9
26. Dieterich DT, Kotler DP, Busch DF, et al. Ganciclovir treatment of cytome-galovirus colitis in AIDS: a randomized, double-blind, placebo-controlled multicenter study. J Infect Dis 1993; 167: 278-82
27. Anderson RD, Griffy KG, Jung D, et al. Ganciclovir absolute bioavail-ability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus and cytomegalovirus-seropositive patients. Clin Ther 1995; 17: 425-32
28. Jung D, Dorr A. Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. J Clin Pharmacol 1999; 39: 800-4